All In Biotech

Drug Trial Radar · NCT06238843

A Multicenter, Phase 3 Study of IBI343 Monotherapy Versus Treatment of Investigator's Choice in Subjects With Previously Treated, Claudin (CLDN) 18.2-positive, HER2-negative, Gastric or Gastroesophageal Junction Adenocarcinoma (G-HOPE-001)

A Multicenter, Randomized, Open-label, Phase 3 Study of IBI343 Monotherapy Versus Treatment of Investigator's Choice in Subjects With Previously Treated, Claudin (CLDN) 18.2-positive, HER2-negative, Locally Advanced, Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma

Last checked: Nov 19, 2026Latest source record: May 13, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingPhase 3. Randomized with 464 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

464

Actual

Start

Jun 30, 2024

Primary completion

Dec 30, 2026

Study completion Dec 31, 2027

Sponsor

Sponsor type
Industry
First posted
Feb 2, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a Multicenter, Randomized, Open-label, Phase 3 Study of IBI343 Monotherapy Versus Treatment of Investigator's Choice in Subjects with Previously Treated Claudin (CLDN) 18.2-positive, HER2-negative, Locally Advanced, Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma to compare the progression free survival (PFS) and overall survival (OS)

Conditions

  • Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma

Interventions

  • Irinotecan OR Paclitaxel or Trifluridine/tipiracil( FTD/TPI)Drug

    Drugs: Irinotecan Subjects in the control arm will receive irnotecan 150mg/m2 IV D1, D15, Q4W in 4-weeks cycles. Drugs: Paclitaxel Subjects in the control arm will receive paclitaxel 80mg/m2 IV D1, D8, D15, Q4W in 4-week cycles, Drugs:FTD/TPI Subjects in the control arm will receive FTD/TPI 35 mg/m2 up to a maximum of 80 mg orally twice a day on Days 1 to 5 and Days 8 to 12, Q4W (applicable in US/EU/Japan and other regions where FTD/TPI is approved for GC treatment).

  • IBI343Drug

    Subjects in the experimental arm will receive IBI343 6mg/kg intravenous infusion (IV) D1, Q3W in 3-week cycles .

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. progression free survival(PFS)Time frame: within approximately 20 months
  2. overall survival(OS)Time frame: within approximately 26 months

Locations

95 sites in 2 countries. Site status is shown where the registry gives one.

  • The First Affiliated Hospital of Bengbu Medical University

    Bengbu, Anhui, China

  • Anhui Provincial Hospital

    Hefei, Anhui, China

  • The First Affiliated Hospital of USTC /Anhui Provincial Hospital

    Hefei, Anhui, China

  • The First Affiliated Hospital of Anhui Medical University

    Hefei, Anhui, China

  • Lu'an People's Hospital of Anhui Province

    Lu'an, Anhui, China

  • The First Affiliated Hospital of Wannan Medical College

    Wuhu, Anhui, China

  • Peking Union Medical College Hospital

    Beijing, Beijing Municipality, China

  • Beijing Cancer Hospital

    Beijing, Beijing Municipality, China

  • Fujian Medical University Union Hospital

    Fuzhou, Fujian, China

  • The First Affiliated Hospital of Fujian Medical University

    Fuzhou, Fujian, China

  • Fujian Cancer Hospital

    Fuzhou, Fujian, China

  • The second hospital of Lanzhou university

    Lanzhou, Gansu, China

  • Gansu Provincial Cancer Hospital

    Lanzhou, Gansu, China

  • Dongguan People's Hospital

    Dongguan, Guangdong, China

  • Guangdong Provincial People's Hospital

    Guangzhou, Guangdong, China

  • Guanxi Medical University Cancer Hospital

    Nanning, Guangxi, China

  • The People's Hospital of Guangxi Zhuang Autonomous Region

    Nanning, Guangxi, China

  • The Fourth Hospital of Hebei Medical University

    Shijiazhuang, Hebei, China

  • The 2nd Affiliated Hospital of Harbin Medical University

    Harbin, Heilongjiang, China

  • Harbin Medical University Cancer Hospital

    Harbin, Heilongjiang, China

  • Nanyang Central Hospital

    Nanyang, Henan, China

  • Puyang People's Hospital

    Puyang, Henan, China

  • The First Affiliated Hospital of Xinxiang Medical University

    Weihui, Henan, China

  • Xinyang Central Hospital

    Xiangyang, Henan, China

  • Henan Cancer hospital

    Zhengzhou, Henan, China

  • The First Hospital of Zhengzhou University

    Zhengzhou, Henan, China

  • Henan Provincial People's Hospital

    Zhengzhou, Henan, China

  • Union Hospital Affiliated to Tongji Medical College, Huazhong University of Science and Technology

    Wuhan, Hubei, China

  • Hubei Cancer Hospital

    Wuhan, Hubei, China

  • Xiangyang Central Hospital

    Xiangyang, Hubei, China

  • Hunan Cancer Hospital

    Changsha, Hunan, China

  • Hunan Provincial Cancer Hospital

    Changsha, Hunan, China

  • Chenzhou No.1 People's Hospital

    Chenzhou, Hunan, China

  • Yueyang Central Hospital

    Yueyang, Hunan, China

  • Zhuzhou Central Hospital

    Zhuzhou, Hunan, China

  • The Affiliated Hospital of Inner Mongolia Medical University

    Hohhot, Inner Mongolia, China

  • The First People's Hospital of Changzhou

    Changzhou, Jiangsu, China

  • The First People's Hospital of Lianyunguang

    Lianyungang, Jiangsu, China

  • Jiangsu Cancer Hospital

    Nanjing, Jiangsu, China

  • The Second Affiliated Hospital of Soochow University

    Suzhou, Jiangsu, China

Showing 40 of 95 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.